Susan Hoe is a Staff Scientist / Associate Director for Inhalation Product Development at AstraZeneca, located in South San Francisco, CA. She currently leads preclinical and early phase development of inhaled biologics, and spray dried formulation platform development within the company. Since joining Pearl Therapeutics (now AstraZeneca) in 2014, Susan has supported product development for Bevespi Aerosphere, Breztri Aerosphere, and PT027 programs, in addition to her work driving the establishment of an inhaled biologics pipeline within AstraZeneca.
Prior to 2014, Susan conducted postdoctoral research into inhaled bacteriophage therapy, and spray dried formulation design via predictive in silico modelling, at the University of Alberta, Canada under Professor Reinhard Vehring. She holds a PhD in Pharmaceutical Science and Bachelor of Pharmacy from the University of Sydney, Australia.